1. Home
  2. NRIX vs DFH Comparison

NRIX vs DFH Comparison

Compare NRIX & DFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.18

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Dream Finders Homes Inc.

DFH

Dream Finders Homes Inc.

HOLD

Current Price

$19.87

Market Cap

1.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
DFH
Founded
2009
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
NRIX
DFH
Price
$19.18
$19.87
Analyst Decision
Strong Buy
Hold
Analyst Count
13
1
Target Price
$26.77
$26.00
AVG Volume (30 Days)
1.9M
342.9K
Earning Date
01-27-2026
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.84
Revenue
$83,687,000.00
$4,671,814,000.00
Revenue This Year
$58.38
N/A
Revenue Next Year
N/A
$1.86
P/E Ratio
N/A
$7.00
Revenue Growth
48.32
15.98
52 Week Low
$8.18
$17.61
52 Week High
$22.50
$31.50

Technical Indicators

Market Signals
Indicator
NRIX
DFH
Relative Strength Index (RSI) 66.53 52.02
Support Level $19.02 $17.75
Resistance Level $22.50 $20.16
Average True Range (ATR) 1.18 0.72
MACD 0.10 0.23
Stochastic Oscillator 52.01 84.46

Price Performance

Historical Comparison
NRIX
DFH

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About DFH Dream Finders Homes Inc.

Dream Finders Homes Inc is engaged in the home building business. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the majority of its revenue from the Midwest segment.

Share on Social Networks: